Resumen de acción 1877 Shanghai Junshi Biosciences Co., Ltd., empresa biofarmacéutica, se dedica al descubrimiento, desarrollo y comercialización de diversos fármacos en las áreas terapéuticas de tumores malignos, enfermedades neurológicas, autoinmunes, metabólicas crónicas, del sistema nervioso e infecciosas en la República Popular China. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Shanghai Junshi Biosciences Co., Ltd. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Shanghai Junshi Biosciences Precios históricos de las acciones Precio actual de la acción HK$12.02 Máximo en las últimas 52 semanas HK$21.70 Mínimo de 52 semanas HK$9.17 Beta 0.41 Cambio en 1 mes -2.75% Variación en 3 meses -1.64% Cambio de 1 año -35.24% Variación en 3 años -74.96% Variación en 5 años n/a Variación desde la OPV -86.62%
Noticias y actualizaciones recientes
Shanghai Junshi Biosciences Co., Ltd. Announces Board and Committee Changes Dec 20 Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) dropped from SSE 180 Index
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong Nov 30 Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong
Third quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.42 loss in 3Q 2023) Oct 30
Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection Oct 14 Ver más actualizaciones
Shanghai Junshi Biosciences Co., Ltd. Announces Board and Committee Changes Dec 20 Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) dropped from SSE 180 Index
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong Nov 30 Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong
Third quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.42 loss in 3Q 2023) Oct 30
Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection Oct 14
Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Sep 26
Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab Sep 24
Second quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.46 loss in 2Q 2023) Aug 31
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma Aug 13
Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets Jul 09
Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Jun 28
Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration Jun 26
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Jun 24
Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer Jun 19
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration Jun 14
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma Jun 13
Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024 May 31
First quarter 2024 earnings released Apr 30 Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
No longer forecast to breakeven Apr 17
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer Apr 10
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection Apr 03
Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 30
Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022) Mar 30
Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022) Feb 24
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023 Feb 01
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer Jan 13 Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board
Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine Jan 10
Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List Dec 13 Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Nov 29
New minor risk - Profitability Nov 09
Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022) Oct 29
Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Oct 28
Shanghai Junshi Biosciences Co., Ltd. Directors Appointments Oct 21
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint Sep 26
Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Sep 12 Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial
Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director Aug 31
Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022) Aug 31
Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Aug 28
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC Jul 12
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Jul 01
Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application Jun 20 Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer May 24
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint May 08
First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022) Apr 30
Now 21% undervalued after recent price drop Apr 11
Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02 Feb 16
Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application Feb 01 Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022 Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China
Now 26% undervalued Jan 03
Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116 Jan 03
Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application Dec 31
Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19 Dec 30
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Dec 26
Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting Dec 13
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Dec 10
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab Dec 06
Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency Nov 25
Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Supplemental Drug Application Issued by the National Medical Products Administration Nov 22
No longer forecast to breakeven Nov 16
Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization Application to the European Medicines Agency for Toripalimab Nov 15
Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration Oct 31
Third quarter 2022 earnings released: CN¥0.75 loss per share (vs CN¥0.50 loss in 3Q 2021) Oct 31
Shanghai Junshi Biosciences Co., Ltd. to Report Nine Months, 2022 Results on Oct 28, 2022 Oct 19
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Oct 13
Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer Sep 21
Forecast breakeven date pushed back to 2024 Sep 03
Second quarter 2022 earnings released: CN¥0.57 loss per share (vs CN¥0.37 loss in 2Q 2021) Sep 01 Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor) Shanghai Junshi Biosciences Co., Ltd. to Report Q2, 2022 Results on Aug 30, 2022
Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma Jul 22
Now 21% undervalued after recent price drop Jul 14
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Issued by National Medical Products Administration Jul 13
Forecast to breakeven in 2024 Jul 13
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Jul 07 Rentabilidad de los accionistas 1877 HK Biotechs Mercado HK 7D -4.6% -2.3% 2.3% 1Y -35.2% -6.0% 22.4%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Los resultados de 1877 fueron inferiores a los de la industria Hong Kong Biotechs, que obtuvo un rendimiento del -6% el año pasado.
Rentabilidad vs. Mercado: 1877 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fueron del 22.4% el año pasado.
Volatilidad de los precios Is 1877's price volatile compared to industry and market? 1877 volatility 1877 Average Weekly Movement 11.5% Biotechs Industry Average Movement 11.5% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.5% 10% least volatile stocks in HK Market 4.0%
Precio estable de las acciones: 1877 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 1877 (12%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Shanghai Junshi Biosciences Co., Ltd., empresa biofarmacéutica, se dedica al descubrimiento, desarrollo y comercialización de diversos fármacos en las áreas terapéuticas de tumores malignos, enfermedades neurológicas, autoinmunes, metabólicas crónicas, del sistema nervioso e infecciosas en la República Popular China. La empresa se fundó en 2012 y tiene su sede en Shanghái (República Popular China).
Mostrar más Resumen de fundamentos de Shanghai Junshi Biosciences Co., Ltd. ¿Cómo se comparan los beneficios e ingresos de Shanghai Junshi Biosciences con su capitalización de mercado? Estadísticas fundamentales de 1877 Capitalización bursátil HK$25.55b Beneficios(TTM ) -HK$1.92b Ingresos (TTM ) HK$1.90b
6.2x Ratio precio-ventas (PS)
-6.2x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 1877 Ingresos CN¥1.79b Coste de los ingresos CN¥622.89m Beneficio bruto CN¥1.16b Otros gastos CN¥2.97b Beneficios -CN¥1.80b
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -1.83 Margen bruto 65.15% Margen de beneficio neto -100.90% Ratio deuda/patrimonio 43.8%
¿Cómo se ha desempeñado 1877 a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/25 01:44 Precio de las acciones al final del día 2024/12/24 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Shanghai Junshi Biosciences Co., Ltd. está cubierta por 19 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Congmin Yuan Citic Securities Co., Ltd. Tan Huan Gan Citic Securities Co., Ltd. Muk Tsz Yung Citigroup Inc
Mostrar 16 más analistas 